{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:21:26Z","timestamp":1780590086197,"version":"3.54.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In hematological patients treated with intensive chemotherapy (CHT), febrile neutropenia (FN) is the primary cause of non-relapse mortality (NRM) due to infections that occur during prolonged neutropenia. Fluoroquinolone (FQ) prophylaxis is still recommended by several guidelines for neutropenic patients because it helps reduce bacterial infection rates and fever episodes, although it does not affect infection-related mortality (IRM). However, in the era of multi-drug resistance (MDR), the use of FQs should be evaluated carefully.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present a retrospective, single-center study based on real-life data that includes 512 intensive chemotherapy treatments and the occurrence of prolonged neutropenia in 236 high-risk (HR) hematological patients treated without FQ prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the entire cohort, we recorded FN in 80.5% of the cases. Among these, 33.7% were attributed to fevers of unknown origin, 45.4% were associated with bloodstream infections (BSIs), 9.0% involved bacterial organ infections, 13.6% were due to fungal infections, and 3.4% were linked to viral infections. Septic shock was observed in 7.6% of the patients. Although we documented a high infection rate, the IRM and overall mortality rates were 3.0% (7\/236) and 9.3% (22\/236), respectively. These rates are comparable to those found in settings where FQ prophylaxis is used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although our cohort was small, our results advocate for the exclusion of FQ prophylaxis in HR hematological patients, without increasing the IRM rate and addressing the risk of life-threatening MDR infections. While we believe it is mandatory to have an efficient protocol for the prompt treatment of FN, our data should encourage hematologists to limit the use of FQ prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2025.1632055","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:30:09Z","timestamp":1760679009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Adele","family":"Santoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Malchiodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Zappone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Zuanelli Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Defina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tumbarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/10428194.2023.2197532","article-title":"Impact of fluoroquinolone administration and gut mucosal colonization on the risk of pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation","volume":"64","author":"Akhmedov","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of Cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.37201\/req\/143.2023","article-title":"Safety of fluoroquinolones","volume":"37","author":"Barber\u00e1n","year":"2023","journal-title":"Rev. Esp. Quimioter."},{"key":"ref5","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"Bennett","year":"2020"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann. Intern. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccc.2013.03.002","article-title":"Infection in neutropenic patients with cancer","volume":"29","author":"Bow","year":"2013","journal-title":"Crit. Care Clin."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejcsup.2007.06.002","article-title":"Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients","volume":"5","author":"Bucaneve","year":"2007","journal-title":"EJC Suppl."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ajh.23661","article-title":"Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes","volume":"89","author":"Buckley","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.clml.2022.08.001","article-title":"Impact of fluoroquinolone prophylaxis on neutropenic fever, infections, and antimicrobial resistance in newly diagnosed AML patients","volume":"22","author":"Caro","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.idh.2019.08.006","article-title":"Bloodstream infections in neutropenic patients with haematological malignancies","volume":"25","author":"Carvalho","year":"2020","journal-title":"Infect Dis Health."},{"key":"ref13","first-page":"236","article-title":"Infectious complications of induction treatment for acute myeloid leukaemia using the \u201c7 + 3\u201d protocol without antibiotic prophylaxis - 15 years of experience of one clinical site","author":"Cernan","year":"2023"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12879-023-08218-8","article-title":"Clinical and microbiological profiles in post-chemotherapy neutropenic fever in hematological malignancy: exploration of clinical phenotype patterns by two-step cluster analysis","volume":"23","author":"Chan","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","article-title":"Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"100","author":"Christopeit","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"168.e1","DOI":"10.1016\/j.jtct.2021.12.012","article-title":"Omitting ciprofloxacin prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation and its impact on clinical outcomes and microbiome structure","volume":"28","author":"Daoud-Asfour","year":"2022","journal-title":"Transplant Cell Ther."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/QCO.0000000000000872","article-title":"New approaches to management of fever and neutropenia in high-risk patients","volume":"35","author":"Douglas","year":"2022","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1002\/cam4.2395","article-title":"Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials","volume":"8","author":"Egan","year":"2019","journal-title":"Cancer Med."},{"key":"ref19","year":"2019"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit. Care Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"CD004386","DOI":"10.1002\/14651858.CD004386.pub3","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"2012","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by aspergillus: 2018 update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enfermed Infecciosas Microbiol Clin."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0199531","DOI":"10.1371\/journal.pone.0199531","article-title":"Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance","volume":"13","author":"Garcia-Vidal","year":"2018","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13054-019-2568-5","article-title":"Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration","volume":"23","author":"Gershkovich","year":"2019","journal-title":"Crit. Care"},{"key":"ref26","volume-title":"Infezioni in ematologia: epidemiologia, profilassi, clinica e terapia. Accademia Nazionale di Medicina., editor","author":"Girmenia","year":"1999"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/cid\/ciy825","article-title":"Fluoroquinolone prophylaxis selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"68","author":"Hakki","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/2278-330X.214584","article-title":"A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: can we predict the organism?","volume":"6","author":"Kalaskar","year":"2017","journal-title":"South Asian J Cancer."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12185-019-02593-2","article-title":"Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index","volume":"109","author":"Kawasaki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jinf.2018.05.004","article-title":"Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014","volume":"77","author":"Kern","year":"2018","journal-title":"J. Infect."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11046-017-0146-4","article-title":"Factors influencing non-albicans Candidemia: a case-case-control study","volume":"182","author":"Kofteridis","year":"2017","journal-title":"Mycopathologia"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac594","article-title":"Effectiveness of quinolone prophylaxis in pediatric acute leukemia and hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"9","author":"Leardini","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","article-title":"8th European conference on infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Lehrnbecher","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1016\/j.bbmt.2020.03.027","article-title":"Fluoroquinolone prophylaxis in autologous stem cell transplantation: worthy of a second look","volume":"26","author":"Maakaron","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1600-0609.2008.01122.x","article-title":"Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases","volume":"81","author":"Malagola","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1007\/s00277-024-06069-0","article-title":"Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation","volume":"103","author":"McClellan","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-017-2297-9","article-title":"Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias","volume":"17","author":"Micozzi","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J. Infect."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1195.e1","DOI":"10.1016\/j.jtct.2024.09.011","article-title":"Antibiotic prophylaxis during allogeneic stem cell transplantation-a comprehensive single center retrospective analysis","volume":"30","author":"Neuerburg","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/16078454.2019.1589706","article-title":"Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis","volume":"24","author":"Owattanapanich","year":"2019","journal-title":"Hematology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12464","article-title":"The role of primary antifungal prophylaxis in patients with haematological malignancies","volume":"20","author":"Pagano","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/AAC.00627-10","article-title":"Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis","volume":"54","author":"Paul","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5368","article-title":"Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance","volume":"345","author":"Phillips","year":"2012","journal-title":"BMJ"},{"key":"ref47","year":""},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-284","article-title":"Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. coli","volume":"13","author":"Saini","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41375-023-01930-z","article-title":"Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis","volume":"37","author":"Santoni","year":"2023","journal-title":"Leukemia"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"6427","DOI":"10.1007\/s00253-022-12175-8","article-title":"Antimicrobial resistance: new insights and therapeutic implications","volume":"106","author":"Sheikh","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14152","article-title":"Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: exploring pros and cons","volume":"25","author":"Singh","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3201\/eid0802.010121","article-title":"Multidrug-resistant Pseudomonas Aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology","volume":"8","author":"Tacconelli","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14740\/jh751","article-title":"Treatment-related mortality from infectious complications in an acute leukemia clinic","volume":"9","author":"Torres-Flores","year":"2020","journal-title":"J Hematol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"106806","DOI":"10.1016\/j.ijantimicag.2023.106806","article-title":"Bloodstream infections due to gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey","volume":"61","author":"Trecarichi","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e0224465","DOI":"10.1371\/journal.pone.0224465","article-title":"Bloodstream infections caused by Escherichia coli in onco-haematological patients: risk factors and mortality in an Italian prospective survey","volume":"14","author":"Trecarichi","year":"2019","journal-title":"PLoS One"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cmi.2014.11.022","article-title":"Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey","volume":"21","author":"Trecarichi","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/QCO.0000000000000038","article-title":"Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact","volume":"27","author":"Trecarichi","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref61","volume-title":"Infezioni batteriche nel paziente ematologico","author":"Tumbarello","year":"2021"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2023.022","article-title":"Levofloxacin prophylaxis versus no prophylaxis in acute myeloid leukemia during post-induction aplasia: a single center study","volume":"15","author":"Urbino","year":"2023","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1007\/s00277-024-05866-x","article-title":"Adult acute leukemia patients with gram-negative bacteria bloodstream infection: risk factors and outcomes of antibiotic-resistant bacteria","volume":"103","author":"Wang","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref64","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJM199909163411207","article-title":"Fever in immunocompromised patients","volume":"341","author":"Weir Restrepo","year":"1999","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1632055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:30:10Z","timestamp":1760679010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1632055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":64,"alternative-id":["10.3389\/fmicb.2025.1632055"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1632055","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1632055"}}